Living in the 21st Century has great benefits compared to decades or eras of the past. Technology rules for this genre of people, but the 21st Century has it’s fair share of negatives as well. Cancer is one of the most deadly diseases of man kind and it has only gotten worse over the past decade. Many of us have been effected or touched by this illness, but there are advancements on the market and in the pipeline for fighting the disease. Seattle Genetics is the name and eradicating cancer is the game.
Seattle Genetics is one of the best Biotechnology companies in the world and it’s antibody based therapies are extending lives. Any great company has to have great leadership and this company is no exception. Dr. Clay Siegall, whom is the President, (CEO), and Co-Founder, has turned this company into a worldwide powerhouse. Dr. Siegall has been in the business for many years and his experience exceeds the vast majority of his peers. He has worked with many of the prominent names in cancer research such as Bristol Myers-Squibb, The National Institute of Health, and The National Cancer Institute. With his extensive knowledge, Dr. Siegall has written over 70 publications all while holding up to 15 patents. The Health Industry has honored this guy with numerous awards and his accolades are phenomenal when compared to other industry leaders.
Even social media is aware of the good doctor’s presence and his social media accounts display a wide range of services that Seattle Genetics offer, breaking news within the industry, statistics of followers, and updates that deal with cancer research. Forbes Magazine has recently stated that the Seattle Genetics is ranked at #71 of the most innovative growth companies in the world. This is the ultimate when it comes to Biotech as the company has a Total Enterprise Value of $4.7 Billion. Clay Siegall is truly a pioneer in the game, but his advanced concepts are very relevant in this digital age.
Mirna Therapeutics is a microRNA in therapeutics company founded in 2007 and is based out of Austin Texas. Mirnas current focus is on cancer research so it came as no surprise when they made the announcement that Clay Seigall would be joining the board of directors as an outside Director. Seigall has been the leading force behind ground breaking cancer treatments and he will be a welcome addition to the Mirna board to provide scientific knowledge as well as practical experience. Seigall received his PHD in genetics from George Washington University and then went on to found Seattle Genetics in 1998 of which he is now the Chief Executive Officer and a board member. Seigall has built Seattle Genetics into a state of the art research firm founded on the principals of integrity, scientific excellence, innovation, teamwork and most importantly helping patients.
With his scientific background, Seigall made the company’s focus about antibody-based therapies for the treatment of cancer. With this focus Seattle Genetics went on the develop the first of its kind antibody drug conjugates (ADCs) that was approved by the FDA in 2011. Seigall then lead the way to form multiple relationships with the larger drug companies to further the development of these treatments. In addition to the multiple collaborations, Seattle Genetics has additional treatments in the pipeline in various phases with the ultimate goal of FDA approval. Seigall is also credited with raising over $675 in both private and public funding to help advance the company’s research efforts.
With the success of Seattle Genetics it is no surprise the Mirna Board wanted Seagalls expertise. In addition to sitting on the board of Mirna, Seigall also joined the board of Ultragenyx in January of 2014. Ultragenyx is a biopharmaceutical company that focuses on research for rare and ultra-rare genetic diseases. Seigall is also a board member of Alder BioPharmaceuticals a therapeutic antibodies research firm dedicated to the treatment of chronic migraines, autoimmune diseases, and inflammatory diseases. It is clear that Seigall has dedicated his life to working with various organizations to help advance the treatment of people who are suffering from various diseases.